SuppreMol launched as a new company
Z-Cube, the corporate venture capital arm of the Zambon Group took another important step forwards in fostering pharmaceutical innovation, signing a contract to provide finance and expert support to SuppreMol GmbH. This marked the project's official launch as a new company after several years of basic research and proof of principle of a new therapeutic approach in autoimmune diseases. SuppreMol is a spin-off company of the Max-Planck-Institute of biochemistry in Munich, Germany set up with the support of Garching Innovation GmbH, the technology transfer office of the Max Planck Society.
SuppreMol is working on the development of drugs for the treatment of autoimmune diseases and allergies through innovative therapeutic approaches centred on Fc -receptors. The development of these drugs is based on patent rights owned by the Max-Planck-Society and licensed to SuppreMol by the Society's Technology Transfer office, Garching Innovation. SuppreMol's principal objective is to prove the therapeutic efficacy of a soluble Fc receptor in the treatment of Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis and other autoimmune diseases.
Other news from the department business & finance
These products might interest you
Rotating ring disk electrode-3A Rotator by C3 Prozess- und Analysentechnik
Precise rotation and easy electrode change - Discover the innovative Rotator system!
VOLTAMMETRY CELLS by C3 Prozess- und Analysentechnik
Replace many sensing elements with our versatile voltammetry cell for precise measurement results
Interface 1010™ by C3 Prozess- und Analysentechnik
Optimize your electrochemical measurements for precise results and a wide range of applications
Reference 620 by C3 Prozess- und Analysentechnik
Potentiostat / Galvanostat / ZRA with maximum sensitivity and minimum noise for pioneering research
